News | Lung Imaging | March 03, 2022

iBiopsy LCS CADe/CADx SaMD could significantly contribute to eliminating barriers to the widespread adoption of lung cancer screening programs and save the lives of millions of patients

Median Technologies announced that the company has filed a 513(g) submission on Feb. 17, 2022, to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx Software as Medical Device (SaMD).

March 3, 2022 — Median Technologies announced that the company has filed a 513(g) submission on Feb. 17, 2022, to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx Software as Medical Device (SaMD).

The 513(g) submission will allow Median Technologies to determine the best product classification and choose between the De Novo or the 510(k) regulatory pathways for iBiopsy LCS CADe/CADx SaMD. The FDA is expected to review the 513(g) submission and provide feedback within 60 calendar days.

As next regulatory steps, Median Technologies is preparing several Q-submissions for Q2, 2022.

“This first regulatory submission marks the beginning of our interactions with the FDA. The FDA’s feedback will help us determine the shortest and most efficient way to bring our product onto the US healthcare market”, Fredrik Brag, CEO and founder of Median Technologies said. “Lung cancer is the deadliest cancer, and being able to detect it very early is of critical importance for patients. Our innovative iBiopsy AI/ML-based technology could have a huge impact on saving patients’ lives by identifying lung cancer onsets at their earliest stage, and could significantly improve the accuracy, consistency, and adoption of lung cancer screening programs worldwide”.

For more information: www.mediantechnologies.com


Related Content

News | Enterprise Imaging

May 24, 2024 — International medical imaging IT and cybersecurity company Sectra’s enterprise imaging solution has been ...

Time May 24, 2024
arrow
News | Radiology Business

May 22, 2024 — Medtronic has announced new preliminary data from the VERITAS clinical study using its ILLUMISITE ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
News | Enterprise Imaging

May 16, 2024 — AGFA HealthCare announced that St. Vincent’s Private Hospital in Dublin, Ireland, has chosen to implement ...

Time May 16, 2024
arrow
News | Artificial Intelligence

May 16, 2024 — deepc, the globally recognized digital medicine pioneer and market leader behind the leading AI operating ...

Time May 16, 2024
arrow
Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | Enterprise Imaging

May 15, 2024 — etherFAX has announced the expansion of its partnership with Hyland, a global provider of intelligent ...

Time May 15, 2024
arrow
News | Cybersecurity

May 13, 2024 — In the wake of the cybersecurity breach targeting the prominent healthcare system Ascension, a new study ...

Time May 13, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients ...

Time May 10, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Subscribe Now